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Abstract: A major challenge in neuronal gene therapy is to achieve safe, efficient, and minimally 
invasive transgene delivery to neurons. In this study, we report the use of a nonviral neurotropic 
poly(ethylene imine)-based nanoparticle that is capable of mediating neuron-specific transfec-
tion upon a subcutaneous injection. Nanoparticles were targeted to peripheral neurons by using 
the nontoxic carboxylic fragment of tetanus toxin (HC), which, besides being neurotropic, is 
capable of being retrogradely transported from neuron terminals to the cell bodies. Nontargeted 
particles and naked plasmid DNA were used as control. Five days after treatment by subcuta-
neous injection in the footpad of Wistar rats, it was observed that 56% and 64% of L4 and L5 
dorsal root ganglia neurons, respectively, were expressing the reporter protein. The delivery 
mediated by HC-functionalized nanoparticles spatially limited the transgene expression, in 
comparison with the controls. Histological examination revealed no significant adverse effects 
in the use of the proposed delivery system. These findings demonstrate the feasibility and safety 
of the developed neurotropic nanoparticles for the minimally invasive delivery of genes to the 
peripheral nervous system, opening new avenues for the application of gene therapy strategies 
in the treatment of peripheral neuropathies.
Keywords: gene therapy, nonviral vector, neuron-targeted, peripheral neurons 
Introduction
Peripheral neuropathy is a clinical condition highly prevalent worldwide that still awaits 
efficient treatment options. Although peripheral neurons have intrinsic regenerative 
capacities, the provision of specific trophic factors to the injured neurons can result in 
a significant improvement in their survival and regeneration efficiency. Nonetheless, a 
reduced plasma half-life and adverse effects in nontargeted tissues as a consequence 
of systemic administration have limited their clinical application.1 An alternative 
approach to achieve a controlled and targeted delivery of trophic factors in the ner-
vous system is the use of gene-based therapies, in which a transgene encoding for a 
therapeutic protein is introduced into the target cells. However, the development of 
safe and efficient vectors for in vivo gene transfer remains a main challenge in order 
to attain the promise of gene therapy. 
Gene transfer to the peripheral nervous system has been previously explored, 
mainly through the use of viral vectors, since some have natural neurotropism and are 
associated with high transduction efficiencies.2 However, in spite of important advances 
toward the increased safety of viral vehicles, they still present risks regarding toxicity 
and immunogenicity.3 In turn, nonviral gene delivery vectors have become attractive 
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alternatives to their viral counterparts, offering better safety 
profiles, although the majority continues to show low gene 
transfer efficiency.4 Together with safety and efficiency 
issues, crucial requirements for in vivo gene therapy are the 
specific targeting of the desired cell population as a way to 
avoid off-target delivery and increase the transgene expres-
sion in the target tissue, assured by a minimally invasive 
administration route. Despite the wide number of nonviral 
gene delivery vectors proposed in the past, to the best of 
our knowledge, none has been developed to actively target 
peripheral neurons following a minimally invasive peripheral 
route of administration. Thus, such development is of signifi-
cant interest not only for safety issues, but also to aid in the 
design of more clinically relevant therapeutic applications to 
treat neuropathic conditions. To this end, we have previously 
described the development of a nonviral gene delivery vector 
based on poly(ethylene imine) (PEI) targeted to peripheral 
neurons by its functionalization with a pegylated nontoxic 
carboxylic fragment of tetanus toxin (HC).5 The HC fragment 
is neurotropic and can undergo active retrograde transport 
after peripheral administration.6,7 Indeed, its potential as a 
therapeutic carrier has already been explored as a coupling 
agent to mediate the transport of proteins or viral vectors 
to neurons.8–10 When functionalized with the pegylated HC 
fragment, the developed thiolated PEI-based nanoparticles 
(PEISH-HC) showed the ability to transfect primary cultures 
of dissociated dorsal root ganglia (DRG) neurons in a specific 
fashion.5 Here, we aimed to evaluate the in vivo performance 
of these targeted nanoparticles, assessing their capacity to 
retrogradely access and transfect lumbar DRG neurons after 
a peripheral and minimally invasive administration in the 
animal’s footpad. We hypothesize that after footpad injec-
tion, the nanoparticles contact the sensorial terminals, are 
internalized in a cell-specific fashion, are transported toward 
the DRGs that innervate the injection site, and lead to the 
local expression of the transgene.
Materials and methods
Materials
Branched PEI (25 kDa, Sigma-Aldrich Co., St Louis, MO, USA) 
was thiolated with 2-iminothiolane (Sigma-Aldrich Co.) and 
purified as previously described.5 The thiolated PEI (PEISH) 
was dissolved at 1 mg/mL in a 5% (w/v) glucose solution 
(pH 7.4) and stored at -80°C until further use. The plasmid 
DNA (pDNA) encoding for GFP and β-galactosidase (pVI-
VO1-GFP-LacZ, 8.4 kb, Invivogen, San Diego, CA, USA) 
was used throughout the study. Plasmid was produced in a 
DH5α competent Escherichia coli strain transformed with 
the respective plasmid. Subsequently, DNA purification was 
performed using an endotoxin-free Maxiprep kit following 
the manufacturer’s instructions (GenElute, Sigma-Aldrich 
Co.). The HC fragment was produced recombinantly using 
the BL21 E. coli strain. The plasmid encoding for the HC 
fragment was a kind offer from Prof Neil Fairweather (King’s 
College, UK). The HC production in the BL21 E. coli strain 
and purification was performed as previously described.11 The 
obtained HC fragment was additionally covalently linked to 
a bi-functional poly(ethylene glycol) (PEG) spacer. Briefly, a 
bi-functional 5 kDa PEG (JenKem Technology USA, Plano, 
TX, USA) bearing an N-hydroxysuccinimide and a maleim-
ide end group was used as indicated by the manufacturer, at 
a 2.5 PEG/HC protein molar ratio.5
Nanoparticles’ preparation
Nanoparticles were prepared as previously described with an 
N/P molar ratio of 3 (N/P – moles of primary amine groups [N] 
of PEI to moles of DNA phosphate groups [P]) and a final con-
centration of 7.5 µg pegylated HC per 2 µg of pDNA.5 Briefly, 
the nanoparticle core was formed by mixing, while vortexing, 
equal volumes of pDNA and PEISH solution in 5% (w/v) 
glucose in water (pH 7.4). Complexes were left to form for 
15 minutes at room temperature. Subsequently, pegylated HC 
fragment (reactive to thiol moieties by a maleimide terminal 
group in the 5 kDa PEG) was added to the complex mixture at 
a final concentration of 7.5 µg per 2 µg of pDNA and ternary 
complexes were left to form for 24 hours at room temperature. 
Prior to use, the nanoparticle dispersion was concentrated to a 
final pDNA concentration of 500 µg/mL in 5% (w/v) glucose 
aqueous solution (pH 7.4) using a 30 kDa cutoff filter (Amicon 
Ultra, EMD Millipore, Billerica, MA, USA).
Nanoparticles’ physicochemical 
characterization
PEISH-based nanoparticles with and without HC function-
alization were characterized in terms of size, polydispersity 
index (Pdi), and zeta potential using a Zetasizer Nano Zs 
(Malvern Instruments, Malvern, UK). The Smoluchowski 
model was applied for zeta potential determination and 
cumulant analysis was used for mean particle size deter-
mination. Ten µg of pDNA was used to prepare the tested 
formulations. All measurements were performed in triplicate 
at 25°C. The morphology of the PEISH-based nanoparticles 
was evaluated by transmission electron microscopy (TEM). 
Briefly, 10 µL of the nanoparticle suspension was placed on 
a grid, treated with sodium phosphotungstate, and observed 
in a TEM Zeiss 902 A. To assess the distribution of the 
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pegylated HC fragment on the surface of the nanoparticle 
core, a parallel experiment was performed in which HC 
fragment was coupled to Qdot® 800 ITK™ carboxyl quan-
tum dots (Molecular Probes, Eugene, OR, USA) before its 
complexation with the thiolated nanoparticles. The resulting 
nanoparticles were adsorbed on a grid and imaged by TEM, 
without any further treatment.
animals and in vivo nanoparticles’ 
administration
All animal experiments were carried out with the permission 
of the local animal ethics committee Instituto de Biologia 
Molecular e Celular (IBMC)-Instituto de Engenharia Bio-
médica (INEB), Associated Laboratory, Porto, Portugal) in 
accordance with the EU Directive (2010/63/EU) and Portu-
guese law (DL 113/2013). The experimental protocol was 
approved by the ethics committee of the Portuguese official 
authority on animal welfare and experimentation (Direção-
Geral de Alimentação e Veterinária). A total of 34 male 
4-month old Wistar rats, with an average weight of 350–400 
g were used in this study. Animals were randomly divided 
into three groups as follows: A) pDNA group (subcutaneous 
injection of pDNA in 5% (w/v) glucose aqueous solution 
(pH 7.4), n=6); B) PEISH group (subcutaneous injection of 
PEISH nanoparticles in 5% (w/v) glucose aqueous solution 
(pH 7.4), n=14); and C) PEISH-HC group (subcutaneous injec-
tion of HC-functionalized PEISH nanoparticles in 5% (w/v) 
glucose aqueous solution (pH 7.4), n=14). For nanoparticles’ 
administration, animals were anesthetized by the inhalation 
of isoflurane and the site of administration was disinfected 
with ethanol. Nanoparticle or pDNA dispersions were admin-
istrated unilaterally in left footpad (150 µL of dispersion 
corresponding to 75 µg of pDNA) using a 25-gauge needle 
(Hamilton, Bonaduz, Switzerland). At 3 and 5 days post-
injection, animals were sacrificed by a lethal intraperitoneal 
injection of 20% (v/v) sodium pentobarbital. In group A, 
and per time point, the tissue samples of two animals were 
processed for gene expression analysis by real-time reverse 
transcriptase-polymerase chain reaction (RT-PCR) and the 
tissue sample of one animal was processed for GFP expression 
detected by immunohistochemistry. In groups B and C, five 
and two animals were used, respectively. Tissues were col-
lected and snap-frozen or fixed in 4% (v/v) buffered formalin 
for total RNA extraction or histological analysis, respectively. 
The following tissues were collected: posterior footpads, 
lymph nodes that drain the back limb region (ie, popliteal and 
inguinal), whole blood, sciatic nerves, L1–L4 ventral roots 
(VR), L4–L5 DRGs, heart, liver, spleen, kidneys, and lungs. 
rNa extraction and real-time rT-Pcr
Total RNA was extracted from designated tissues using the 
PureLink RNA Mini kit (Thermo Fisher Scientific, Waltham, 
MA, USA) according to the manufacturer’s instructions. 
Reverse transcription was obtained from 500 ng of total RNA 
employing the Superscript First-Strand Synthesis System 
(Thermo Fisher Scientific). For real-time quantification of 
GFP mRNA levels, the synthesized complementary DNAs 
were amplified in duplicate in an iCycler iQ5 (Bio-Rad 
Laboratories Inc., Hercules, CA, USA) using iQ SYBR 
Green Supermix (Bio-Rad Laboratories Inc.). The following 
gene sequences were designed and synthesized: GFP sense 
primer: 5′-CTGTCCAACTGGCAGACCATTACC-3′, anti-
sense primer: 5′-TTCCTGCTGCTGTCACAAACTCC-3′; 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
sense primer: 5′-TTCACACCCATCACAAACAT-3′, anti-
sense primer: 5′-GCCATCAACGACCCCTTCAT-3′. At 
the end of the PCR cycling, correspondent melting curves 
were performed in order to ascertain the amplification of a 
single product and the absence of primer dimer formation. 
GAPDH gene was used as an internal control to normalize 
the variability in expression levels. The relative GFP mRNA 
expression levels in treatment groups were calculated relative 
to the control naked pDNA group using the 2-ΔΔCT method 
described by Livak and Schmittgen, normalized with the 
average expression of GAPDH.12
histological analysis
Formalin-fixed tissues were processed and embedded in paraf-
fin to prepare 4 µm paraffin sections. Dewaxed tissue sections 
were prepared for hematoxylin and eosin staining (ie, footpads) 
or for immunohistochemistry to detect the expression of GFP 
protein in the DRGs. The hematoxylin and eosin-stained foot-
pad sections were used to qualitatively analyze the inflamma-
tory response in the injection site as a result of the nanoparticle 
administration. The immunodetection of GFP protein in DRGs 
was used to calculate the in vivo transfection efficiency of 
DRGs mediated by PEI-based nanoparticles. Polyclonal rab-
bit anti-GFP (1:500, A11122, Thermo Fisher Scientific) and 
secondary antibody peroxidase polymer-labeled anti-rabbit 
(Dako Denmark A/S, Glostrup, Denmark) were used. The 
antibody reaction was revealed with diaminobenzidine (Vector 
Laboratories, Burlingame, CA, USA) and tissue sections were 
counterstained with hematoxylin. To determine the transfec-
tion efficiency of PEISH-HC nanoparticles, the number of GFP 
positive L4 and L5 DRG neurons were counted in each 150 µm 
section for each sample. This corresponds to 5–6 sections and, 
on average, 1,000 neurons counted per DRG.
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statistical analysis
Statistical analysis was performed using GraphPad Prism 
version 5.0 for Windows (GraphPad Software, Inc., La 
Jolla, CA, USA). Results are presented as mean ± standard 
deviation. D’Agostino and Pearson omnibus normality tests 
were used to test whether data obeyed a Gaussian distribution. 
The non-parametric Mann–Whitney U-test was performed 
to compare treatment groups. A result with P,0.05 was 
considered statistically significant.
Results and discussion
The strategy followed for the development of neurotropic 
PEISH-based nanoparticles has been previously described 
by us.5 As a first step, the PEISH is complexed with a pDNA 
suspension resulting in a naked complex. In the second step, 
the thiol-decorated complex is functionalized with the HC 
fragment via a 5 kDa bi-functional PEG linker, which is 
thiol-reactive, resulting in the formation of a targeted complex 
(Figure 1A). Here, we explored the in vivo performance of the 
proposed PEISH neurotropic nanoparticles, prepared at an N/P 
ratio of 3. This formulation was chosen as it has been previ-
ously shown, based on molecular recognition force spectros-
copy studies,13 to possess an optimal targeting profile toward 
neuronal cells in vitro, as well as mediating targeted sensory 
neuron cell transfection in dissociated DRG primary cultures.5 
The tested nanoparticle formulations – the neurotropic nano-
particles based on PEISH-HC and the nontargeted PEISH 
based nanoparticles – were fully characterized in terms of 
size, Pdi, zeta potential, and morphology. In Figure 1B the 
presented table summarizes the physicochemical character-
ization of both formulations. The mean size diameter values 
obtained were 63.0±5.5 nm for naked nanoparticles and 
63.0±6.0 nm for PEISH-HC nanoparticles, with the respective 
Pdi values 0.35±0.03 and 0.32±0.03. The mean diameter of 
Figure 1 PeIsh-based nanoparticle characterization. 
Notes: (A) Scheme of nanoparticle synthesis. Modified from Oliveira H, Fernandez R, Pires LR, et al; Targeted gene delivery into peripheral sensorial neurons mediated by 
self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c; J Control Release; 143; 350–358; elsevier; copyright © 2010.5 (B) Physicochemical 
characterization of PeIsh-based nanoparticles at N/P ratio of 3 (n=3, mean ± sD). (C) TeM photo micrographs of sodium phosphotungstate counterstained PeIsh-hc 
nanoparticles (a) and hc-quantum dots functionalized nanoparticles (b).
Abbreviations: PeIsh, thiolated poly(ethylene imine); Pdi, polydispersity index; N/P, moles of primary amine groups (N) of poly(ethylene imine) to moles of DNa phosphate 
groups (P); sD, standard deviation; TeM, transmission electron microscopy; hc, carboxylic fragment of tetanus toxin.
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PEISH-HC nanoparticles is not significantly different than 
the naked nanoparticles showing that HC-functionalization 
does not influence the size of the nanoparticles. Zeta potential 
values obtained for naked and PEISH-HC nanoparticles were 
24.5±4.0 and 27.9±5.0 mV respectively, indicating a cationic 
surface charge of nanoparticles with a good colloidal stability. 
The morphology of both nanoparticle formulations was 
assessed by TEM. In Figure 1C(a) a photomicrograph depicts 
PEISH-HC nanoparticles, being a representative image of 
the observed nanoparticle populations. These exhibited a 
spherical shape with no signs of aggregation. In Figure 1C(b), 
one can observe that the HC moieties grafted to the nanopar-
ticles core are disposed at the surface of the nanoparticles, 
supporting the previously gathered evidences that the presence 
of the HC fragment at the nanoparticle surface confers the 
targeting features to these nanoparticles.
A single dose of naked pDNA, PEISH, or PEISH-HC 
nanoparticle dispersion in 5% (w/v) glucose aqueous solu-
tion (pH 7.4), carrying 75 µg of pVIVO1-GFP-LacZ pDNA, 
was injected in the left footpad of adult Wistar rats. Previous 
studies regarding the peripheral administration of cationized 
gelatin-based nanoparticles reported transgene expression 
from 60 hours to 6 days post-posterior rat footpad injection.14 
In order to assess the ability of developed nanoparticles to 
efficiently access DRG neuron cell bodies after peripheral 
administration in the footpad, we evaluated the GFP trans-
gene expression in the sciatic nerves, VR, and DRGs at 
3 and 5 days post-administration.
In the case of animals treated with pDNA alone, the GFP 
expression was not detected in the sciatic nerve, VR, and DRG 
either at 3 or 5 days post-administration (data not shown). 
With regard to PEISH nanoparticles, at 3 days post- 
administration, a 1 and 4.3 average fold increase in GFP 
expression levels (relative to the expression levels in naked 
pDNA control group) could be detected in the sciatic nerves 
and DRGs, respectively (Figure 2A, C). Conversely, at 
day 5, no GFP expression was observed in the analyzed tissues 
(Figure 2B, C). Animals treated with the PEISH-HC nanopar-
ticles showed a 9 and 2.8 average fold increase in GFP expres-
sion at the VR and DRGs at day 3, respectively (Figure 2A, C). 
Over the course of time, the GFP expression levels in DRGs 
further increased to four-fold (Figure 2B, C). These results 
proved that the transgene could be detected in DRGs as early 
as 3 days after footpad injection, and suggest that HC-grafted 
nanoparticles were retrogradely transported within the rate of 
fast active retrograde axonal transport (100–250 mm per day),15 
as passive diffusion could not account for the covered distance. 
Indeed, it has been shown that the nerve length from the toe to 
the dorsal root entry was in the range of 17 cm in an adult rat,16 
what implies an active retrograde transport of the nanoparticles 
in order to reach the DRG in the observed period of time. At 
day 5, the transgene expression levels in DRG increased in 
relation to day 3 and, additionally, immunohistochemistry 
analysis at this time point showed that the transgene reporter 
protein could be detected (Figure 2D(a) and (b)).
Based on these results, we propose that the HC-functionalized 
nanoparticles were internalized at neuron terminals and fol-
lowed retrograde fast axonal transport to the sensorial neuron 
cell bodies where they accumulated and led to transgene expres-
sion. Previous studies reported the ability of naked PEI-based 
nanoparticles to be retrogradely transported after subcutaneous 
administration in the footpad.14 Our results are in accordance 
with these data, showing that naked PEISH-based nanoparticles 
were also able to deliver the GFP gene into DRGs, but they 
were not as efficient as their targeted counterparts and did not 
persist over time or resulted in reporter protein translation at 
detectable levels (Figure 2D(c) and (d)).14,17,18
One of the major limitations identified in nonviral gene 
delivery vectors is their inefficient transfection capacity. Here, 
we have shown that the developed neuron-targeted PEISH-HC 
nanoparticles were able to mediate the transfection and protein 
expression of 56% and 64% of L4 and L5 DRG neurons at 5 
days post-administration (Figure 2E). The L4 and L5 DRG neu-
rons are the ones which contribute more to the sciatic nerve that 
innervates the footpad.19 A previous study regarding the subcu-
taneous footpad administration of recombinant adeno-associated 
serotype 6 viruses reported a transduction efficiency of L4 DRG 
neurons at less than 10%, at 3 weeks post-administration.20 Also, 
the subcutaneous injection of cationized gelatin-based nano-
particles resulted in a transfection efficiency of approximately 
10% of L4 and L5 DRG neurons.14 These results highlight the 
improved transfection efficiency achieved in this work by means 
of active targeting toward peripheral neurons. 
As important as the ability to reach the target tissues, is 
the capacity to reduce off-target distribution. In this sense 
we evaluated the transgene biodistribution profile, mediated 
by naked pDNA, PEISH, or PEISH-HC nanoparticles, upon 
subcutaneous administration, by assessing GFP mRNA 
expression in the following non-neuronal tissues: injected 
paws, left popliteal and inguinal lymph nodes (which drain 
the injected paws), whole blood, heart, liver, spleen, kidneys, 
and lungs. At 3 days post-injection, animals administered 
with pDNA alone revealed GFP gene expression solely in the 
injected paws (Figure 3A). However, at day 5, the transgene 
expression was detected in the majority of the tissues evaluated 
(Figure 3B). In PEISH-treated animals, the GFP transgene 
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Figure 2 reporter gene expression in neuronal tissues. 
Notes: relative GFP gene expression in neuronal tissues was evaluated at 3 (A) and 5 days (B) post-administration of PeI-based nanoparticles in the left footpad. (C) statistical 
data characterization (n=5). (D) gFP protein expression in lumbar Drgs from animals treated with PeIsh (c, d) or PeIsh-hc nanoparticles (a, b) at 5 days post-
administration. (E) Transfection efficiency of lumbar L4 and L5 DRG neurons mediated by PEISH-HC nanoparticles at day 5 post-administration. Mean ± sD. (A and B) The 
GFP mrNa expression levels were normalized by GAPDH mrNa expression levels in each tissue sample and represented as relative to the GFP expression in naked pDNa 
control group. We considered the sciatic nerves, Vr, and l4–l5 Drg as neuronal tissue. each dot represents one animal. **Denotes P,0.01; lines represent the geometric 
mean. (D) #Indicates a GFP positive cell; ¤indicates a GFP negative cell. Scale bars =100 µm (a, c) or 25 µm (b, d). 
Abbreviations: PeI, poly(ethylene imine); PeIsh, thiolated poly(ethylene imine); GAPDH, glyceraldehyde 3-phosphate dehydrogenase; pDNa, plasmid DNa; Vr, ventral 
roots; DRG, dorsal root ganglia; SD, standard deviation; CI, confidence interval; HC, carboxylic fragment of tetanus toxin.
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Targeted gene delivery to peripheral neurons
could be detected in the injected paws, lymph nodes, heart, 
and liver at 3 and 5 days post-administration, and additionally 
in blood and spleen at 3 days post-administration (Figure 3). 
In contrast with these observations, animals treated with 
HC-functionalized PEISH nanoparticles revealed a restricted 
expression of GFP mRNA in non-neuronal tissues. As illus-
trated in Figure 3, the transgene expression was only detected 
in the injected paws and lymph nodes at both time points, 
and in the blood at 5 days post-administration. Moreover, 
the GFP gene expression levels in paws and lymph nodes 
were considerably lower in animals treated with PEISH-HC 
nanoparticles at both time points (Figure 3C, D). These results 
further support that HC-functionalized nanoparticles are able 
to spatially limit the transgene expression, in comparison 
with the nontargeted nanoparticles and naked pDNA, signifi-
cantly reducing the possibility of unwanted off-target effects. 
To further assess the impact of the local administration of the 
developed vectors, we evaluated the inflammatory response 
in the footpad at 3 and 5 days post-administration. In the first 
hours post-administration, independently of the tested formula-
tion, animal footpads presented a moderate swelling indicative 
of a mild inflammatory reaction as a consequence of the injec-
tion, but 24 hours later the rat footpads regained their normal 
appearance and the animals showed normal use of the limb. 
Histologic analysis of the footpad at 3 and 5 days post-injection 
showed infiltration of inflammatory cells in the injection site 
(Figure 4). However, no relevant differences were observed 
between treatment groups, and the general behavior of ani-
mals under the tested conditions indicated that the developed 
systems do not induce a harmful effect, with neither footpad 
sensitization nor significant animal weight variation (data not 
shown) being observed, suggesting their safety.
Figure 3 (Continued)
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Figure 4 Inflammatory response in the injection site. 
Notes: representative images of footpad subcutaneous tissue at 3 days (A, D, and G, scale bars =100 µm) and 5 days (B, E, and H, scale bars =100 µm; and C, F, and I, scale 
bars =20 µm) post-administration of naked pDNa (A–C), PeIsh nanoparticles (D–F) or PeIsh-hc nanoparticles (G–I). Arrowheads indicate the presence of infiltrating 
inflammatory cells.
Abbreviations: pDNa, plasmid DNa; PeIsh, thiolated poly(ethylene imine); hc, carboxylic fragment of tetanus toxin.
??????
? ? ?
? ? ?
? ? ?
???
?
???
??
???
???
??
?????? ??????
Figure 3 reporter gene expression in non-neuronal tissues. 
Notes: Firstly, GFP mRNA expression profile was qualitatively evaluated in non-neuronal tissues at 3 (A) and 5 (B) days post-administration. relative GFP gene expression 
in paw (C) and lymph nodes (D) at 3 and 5 days post-administration of PeI-based nanoparticles in the left footpad. (A and B) For each tissue, over the columns, the number 
of animals expressing GFP mrNa in relation to the total number of animals evaluated is indicated (ie, 1/5 indicates one animal expressing GFP mRNA in a total of five animals 
analyzed at the same time point). (C and D) *Denotes P,0.05; lines represent the geometric mean.
Abbreviations: pDNa, plasmid DNa; PeI, poly(ethylene imine); PeIsh, thiolated poly(ethylene imine); hc, carboxylic fragment of tetanus toxin.
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Conclusion
This study demonstrates the efficient and targeted delivery 
of a reporter gene mediated by HC-modified PEISH-based 
nanoparticles to DRG sensorial neurons through a peripheral 
administration in the footpad. Likewise, these neurotropic 
nanoparticles can be used to carry plasmids encoding for 
any relevant therapeutic gene in the nervous system, such 
as genes encoding for the neurotrophins NGF21 and BDNF,5 
or pain-relief associated genes like PENK.22 Such a targeted, 
versatile, and minimally invasive approach may prove to be 
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Targeted gene delivery to peripheral neurons
useful for exploring new therapeutic strategies valuable for 
the treatment of sensory neuropathy, by stimulating sensory 
axon regeneration and/or preventing neuronal degeneration 
in the DRG, as well as for the relief of pain states resulting 
from various clinical conditions.
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